Soliton, Inc, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (MD Anderson), released interim clinical trial results presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting on October 24, 2019.  

During our keloid and hypertrophic scar (also known as “fibrotic scars”) proof-of-concept trial, we treated 10 people, each of whom received just a single 6-minute treatment with our Rapid Acoustic Pulse (“RAP”) device. 

Read the full press release at